2. The Vitamin D3 Regimen ("Batch Protocol")

History and originator

The regimen is attributed to Pete Batcheller, a retired US Navy fighter pilot and call-sign “Batch,” a chronic CH sufferer who began the protocol around 2011–2015 and shared it within the community community report19. It is a daily anti-inflammatory supplement stack centred on high-dose vitamin D3 (cholecalciferol), typically alongside omega-3 fish oil and other cofactors, targeting a serum 25-hydroxyvitamin D (25(OH)D) concentration around 80 ng/mL, well above standard “sufficiency” reference ranges citizen science2021.

Loading protocols

Two accelerated loading schedules are documented on Clusterbusters’ own resource page: a two-week schedule (50,000 IU/day in week 1, tapering to 10,000 IU/day maintenance) and a four-week schedule (20,000 IU/day plus weekly 50,000 IU boosters, tapering to 15,000 IU/day then to 10,000 IU/day maintenance) citizen science20. Dose adjustments by BMI are also specified: subtract 100,000 IU total loading dose if BMI <18.5; add 100,000 IU if BMI >25 citizen science20. These same protocols have been translated into German by the Austrian patient site clusterkopfschmerzen.at, indicating cross-language community uptake community report11.

The published survey evidence

A conference abstract (Neurology, 2014) reported results from a structured survey of 110 CH sufferers using the daily anti-inflammatory D3 regimen citizen science21:

• 80% reported significant reductions in frequency, severity, and duration of CH
• 60% reported remaining substantially pain-free
• Average starting 25(OH)D was 23.4 ng/mL; average response level after ≥30 days was 76 ng/mL
• Efficacy was slightly higher in episodic (85%) than chronic (70%) CH
• A “stress test” of D3 reserves after 13 months pain-free led to a return of CH within 8 days of stopping supplementation
• 33% reported comorbidities; no major adverse events were reported citizen science21

This was a conference abstract, not a full peer-reviewed journal article — it is labelled here as citizen science rather than peer-reviewed because it did not undergo full journal peer review and has not, as far as located sources show, been followed by a full published paper. It is frequently cited in review articles (e.g., a 2021 systematic review on vitamin D and primary headache) as the sole cluster-specific data point on this regimen, categorised there as a “prospective” report peer-reviewed22.

Formal trial activity

A registered clinical trial, “High Dose Vitamin D Plus Multivitamin in the Prevention of Cluster Headache” (ClinicalTrials.gov NCT04570475, Houston, Texas, PI Dr Mark J. Burish, UTHealth), was designed as a double-blind, placebo-controlled study of high-dose D3 plus multivitamin against placebo plus multivitamin, using change in weekly attack frequency as its primary outcome preprint / trial2322. Update (checked August 2026): the trial’s ClinicalTrials.gov record now shows status TERMINATED, with the stated reason “Low number met criteria to randomize” preprint / trial23. It had actually started 15 September 2021, reached actual completion 13 May 2024, and randomised only 27 participants; the record shows no posted results and no linked publication preprint / trial23. No abstract, preprint, or journal article reporting outcome data from this trial could be located. This is a notable and somewhat ironic outcome: the trial meant to formally test the community’s D3 protocol seems to have failed on recruitment at least partly because so many CH patients already self-supplement with high-dose D3 outside the trial, making it hard to find enough D3-naïve, protocol-eligible candidates to randomise — a citizen-science practice arguably undermining its own formal validation. This inference about the recruitment mechanism is not stated in the registry record itself and should be read as this document’s own reasoning, not a sourced fact.

Separately, vitamin D3 supplementation has been tested in randomised controlled trials for migraine (not cluster headache specifically): a 2018 trial found D3 (100 μg/day) superior to placebo in reducing migraine days over 24 weeks peer-reviewed24, and a 2020 Iranian trial of 2000 IU/day for 12 weeks in episodic migraine found improved headache characteristics and reduced some inflammatory markers (iNOS, borderline IL-6), though not others (IL-10, Cox-2) peer-reviewed25. These findings are suggestive by analogy but are not cluster headache data and should not be read as confirming the Batch protocol’s specific claims.

Proposed mechanism and evidence quality assessment

The proposed mechanism is anti-inflammatory: vitamin D is theorised to modulate cytokine and neuro-inflammatory pathways implicated in trigeminal-autonomic activation, with the migraine trial data offering partial (inconsistent) support for reduced inflammatory markers peer-reviewed25. However, the flagship cluster-specific evidence (the 110-person survey) is: uncontrolled, unblinded, self-selected (participants had to find and enrol via patient community channels), and reported only as a conference abstract citizen science21. This is a highly promising, well-organised, and rigorously described piece of citizen science — but it falls well short of the double-blind, placebo-controlled standard needed to establish causation, and the one registered RCT that attempted to resolve this (NCT04570475) was terminated on recruitment grounds in 2024 without reporting results preprint / trial23. Honest assessment: plausible, patient-organised, promising, but now formally untested and unlikely to be resolved by the one trial designed to test it — a rarer and more discouraging outcome than “pending,” and worth flagging clearly rather than letting the original “awaiting results” framing stand uncorrected.